

A study of JNJ-80038114 in participants with advanced stage prostate cancer

Submission date 04/01/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/01/2023	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 24/04/2024	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The purpose of this study is to see if a new study drug can be used in future studies for the treatment of prostate cancer. During the study, side effects caused by the study drug will be followed closely, as well as how long the study drug stays in the body and how the body responds to it.

This is the first time that the study drug is being tested in humans. It is not approved for use by humans in any country.

Therefore, Part 1 of the study will start with the administration of a low dose of the study drug. After reviewing the results obtained at each dose level, it will be decided whether or how much to increase the dose for subsequent participants.

Who can participate?

This study will include participants aged 18 years and over with metastatic castration-resistant prostate cancer.

What does the study involve?

This study consists of a screening phase, a treatment phase and an end-of-treatment visit. All participants will receive the study drug via subcutaneous (below the skin) injections. The dose and frequency of the injections will depend on when a participant enters the study.

The duration of participation is determined by the duration of the study drug administration. Administration of the study drug will last as long as a participant benefits and does not have unmanageable side effects. In addition, participants and physicians can decide to stop the study drug at any time.

At study visits, a participant will have procedures such as blood and urine tests, ECG, physical exam, CT / MRI or bone scan. An additional fresh tumour biopsy may be collected during Part 2 of the study. Hospitalisation will also be required to monitor for any side effects during the first one or more doses of the study drug in Part 1.

What are the possible benefits and risks of participating?

This is the first study of this study drug in humans. It is possible that taking part in this study could improve a participant's condition, but this is not guaranteed to happen.

During the study, a participant's condition may stay the same or get worse.

Based on clinical trials of other active substances that target prostate specific membrane antigen (also referred to as PSMA, a common protein in patients with prostate cancer) and the immune system, potential side effects have been outlined in the participant information sheet. This sheet will be signed by every participant agreeing to participate in the study and includes a section describing these potential side effects.

This is the first time the study drug will be given to humans, so we do not yet know if these potential side effects will occur or how frequently they may occur. Different side effects may occur. There may be risks to using the study drug that we don't know yet.

Tests and procedures will be done during the study to monitor side effects. Participants will also be educated to report any symptoms they experience during the study to their study doctor, even if they do not think the side effects are related to the study drug or procedures.

Where is the study run from?

Janssen Research & Development, LLC (Belgium) is the Sponsor of this study.

Participating centers (Hospitals) are located in the UK, US, France and Germany.

When is the study starting and how long is it expected to run for?

January 2022 to September 2024

Who is funding the study?

Janssen Research & Development, LLC (Belgium)

Who is the main contact?

Larissa Bates, janssenukregistryqueries@its.jnj.com

Contact information

Type(s)

Scientific

Contact name

Dr Medical Information & Product Information Enquiry

Contact details

50-100 Holmers Farm Way

High Wycombe

United Kingdom

HP12 4EG

+44 8007318450 / +44 1494567444

medinfo@its.jnj.com

Type(s)

Public

Contact name

Mrs Larissa Bates

Contact details

50-100 Holmers Farm Way

High Wycombe

United Kingdom

HP12 4EG
+44 1494567444
janssenukregistryqueries@its.jnj.com

Type(s)

Principal Investigator

Contact name

Dr Andrew Hudson

Contact details

The Christie NHS Foundation Trust
Wilmslow Road
Manchester
United Kingdom
M20 4BX

Additional identifiers

EudraCT/CTIS number

2022-001263-27

IRAS number

1005794

ClinicalTrials.gov number

NCT05441501

Secondary identifying numbers

80038114PCR1001, IRAS 1005794, CPMS 53090

Study information

Scientific Title

A phase 1 study of JNJ-80038114, a T-Cell redirecting agent targeting prostate specific membrane antigen (PSMA), for advanced stage prostate cancer

Study objectives

The main goals of this study are:

1. To determine the appropriate doses of the study drug and,
2. To evaluate any side effects.

The secondary goals of this study are:

1. To evaluate the cancer cells' response to the study drug and,
2. To provide an understanding of how the body reacts to the study drug and how long the study drug remains in the body.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 03/10/2022, West London and GTAC Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 207 1048 007; westlondon.rec@hra.nhs.uk), ref: 22/LO/0556

Study design

Interventional non-randomized open-label multicenter study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Prostate cancer

Interventions

The study is split into two parts:

Part 1, dose-escalation: Participants will receive JNJ-80038114. The dose levels will be escalated based on the dose-limiting toxicities (DLTs) observed and then reviewed by the study evaluation team (SET).

Part 2, dose expansion: Participants will receive JNJ-80038114 at the recommended Phase 2 dose (RP2D) determined in Part 1.

Duration of participation is determined by the duration of study drug administration: administration of the study drug will last as long as a participant is receiving benefit and does not have unmanageable side effects. In addition, participant and physician can decide to stop the study drug at any time. There will be just one FU visit at 30-days post treatment.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

JNJ-80038114

Primary outcome measure

The timeframe for monitoring/measuring each of these is up to 2 years and 6 months:

Parts 1 and 2:

1. Number of Participants With Adverse Events (AEs). An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
2. Number of Participants With AEs by Severity. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and associated neurologic toxicity events will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines.

Part 1 only:

3. Number of Participants With Dose-Limiting Toxicity (DLT) . Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Secondary outcome measures

The timeframe for monitoring/measuring each of these is up to 2 years and 6 months:

1. Serum Concentration of JNJ-80038114 - Serum concentration of JNJ-80038114 will be determined.
2. Systemic Cytokine Concentrations - Cytokine concentrations will be determined for biomarker assessment.
3. Serum Prostate Specific Antigen (PSA) Concentration - Serum PSA concentration will be determined.
4. Number of Participants With Antibodies to JNJ-80038114 - Serum samples will be analysed for the detection of antibodies to JNJ-80038114 using a validated assay method.
5. Objective Response Rate (ORR) - ORR is defined as the percentage of participants who have a partial response (PR) or better according to Prostate Cancer Working Group 3 (PCWG3) response criteria.
6. PSA Response Rate - PSA response rate is defined as the percentage of participants with a confirmed decline in PSA of 50 percent (%) or more from baseline.
7. Duration of Response (DOR) - DOR is defined as the duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 response criteria, or death due to any cause, whichever occurs first.

Overall study start date

05/01/2022

Completion date

29/09/2024

Eligibility

Key inclusion criteria

1. 18 years and older
2. Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by Prostate Cancer Working Group 3 (PCWG3)
3. Measurable or evaluable disease
4. At least 1 prior treatment for mCRPC

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
6. Adequate organ functions as defined by certain laboratory values
7. Must sign an informed consent form (ICF)
8. Participants must agree to use a highly effective form of birth control as guided by the study doctor

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Male

Target number of participants

90

Total final enrolment

49

Key exclusion criteria

1. Concurrent anticancer therapy
2. Severe or long-lasting side effects related to prior anticancer therapy
3. Known allergies to JNJ-80038114 or its excipients
4. Brain metastasis or known seizure history
5. Significant infections or lung, heart or other medical conditions

Date of first enrolment

14/12/2022

Date of final enrolment

19/01/2024

Locations**Countries of recruitment**

England

France

Germany

United Kingdom

United States of America

Study participating centre
The Christie NHS Foundation Trust - Christie Hospital
Manchester
United Kingdom
M20 4BX

Study participating centre
The Royal Marsden Hospital
Sutton
United Kingdom
SM2 5PT

Study participating centre
University College London Hospital (ULCH)
London
United Kingdom
NW1 2PG

Study participating centre
Sarah Cannon Research Institute
Nashville
United States of America
37203

Sponsor information

Organisation
Janssen-Cilag International NV

Sponsor details
Turnhoutseweg 30
Beerse
Belgium
2340
+32 14602111
prderacta@prdgb.jnj.com

Sponsor type
Industry

Funder(s)

Funder type

Industry

Funder Name

Janssen-Cilag International NV

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal.

Intention to publish date

29/09/2025

Individual participant data (IPD) sharing plan

The datasets generated and analysed during the current study will be available upon request. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at <https://www.janssen.com/clinical-trials/transparency>. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at yoda.yale.edu.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No